PRAXPraxis Precision Medicines, Inc.

1. Jul 7, 2026On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and license agreement (the “Agreement”) with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems (“Remagine”), to develop an iontophoretic …Other event · Form 8-K
2. Jul 2, 2026Dismissal of Independent Registered Public Accounting Firm On June 29, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of Praxis Precision Medicines, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm …Auditor change · Form 8-K
3. Jun 29, 2026On June 29, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) notified the Company that it has extended by three months the review period for its New Drug Application (“NDA”) for relutrigine for the treatment of SCN2A and SCN8A developmental and …Other event · Form 8-K
4. Jun 22, 2026On June 22, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (“BTD”) for elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (“DEE”) …Other event · Form 8-K
5. Jun 1, 2026On June 1, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures (“FOS”)Other event · Form 8-K
6. Apr 14, 2026On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration (the “FDA”) has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults.Other event · Form 8-K
7. Apr 6, 2026Praxis Precision Medicines, Inc. (the “Company”) is providing the following business updates: Elsunersen The Company announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A development and epileptic encephalopathy (“DEE”)Other event · Form 8-K
8. Feb 10, 2026On January 8, 2026, Praxis Precision Medicines, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) disclosing that the Board of Directors of the Company (the “Board”) elected Jeffrey B. Kindler and Stuart A. Arbuckle to the Board, each as a Class II director, effective January 8, 2026.Director or officer change · Form 8-K/A

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.